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Human cytomegalovirus (HCMV) is an important human pathogen
and a paradigm of intrinsic, innate, and adaptive viral immune
evasion. Here, we employed multiplexed tandem mass tag-based
proteomics to characterize host proteins targeted for degradation
late during HCMV infection. This approach revealed that mixed
lineage kinase domain-like protein (MLKL), a key terminal media-
tor of cellular necroptosis, was rapidly and persistently degraded
by the minimally passaged HCMV strain Merlin but not the exten-
sively passaged strain AD169. The strain Merlin viral inhibitor of
apoptosis pUL36 was necessary and sufficient both to degrade
MLKL and to inhibit necroptosis. Furthermore, mutation of
pUL36 Cys131 abrogated MLKL degradation and restored necrop-
tosis. As the same residue is also required for pUL36-mediated
inhibition of apoptosis by preventing proteolytic activation of
procaspase-8, we define pUL36 as a multifunctional inhibitor of
both apoptotic and necroptotic cell death.
human cytomegalovirus | cell death | necroptosis | protein degradation |
MLKL
Human cytomegalovirus (HCMV) infects the majority of theworld’s population, with a seroprevalence of 60 to 80% in
Western Europe and the United States, and up to 100% in de-
veloping countries (1, 2). Following primary infection, a latent
infection is established that persists lifelong. Reactivation from
latency to productive infection in immunocompromised people
can lead to significant morbidity or mortality, in addition to al-
lograft rejection in transplant recipients (3, 4). Furthermore,
HCMV is the commonest infectious cause of congenital disease,
affecting ∼1/200 pregnancies (5).
Only four drugs are approved by the FDA to treat HCMV,
and all are associated with significant toxicity and the threat of
drug resistance (2, 6). Small molecule-based disruption of in-
teractions between antiviral host proteins and their viral antag-
onists could facilitate endogenous inhibition of viral replication
(7, 8). Identification and detailed characterization of such in-
teractions thus has important implications for the development
of novel anti-HCMV therapies.
HCMV encodes 170 canonical protein-coding genes (2). A
substantial number of additional, noncanonical open reading
frames (ORFs) that potentially encode proteins have been
identified by ribosomal footprinting and proteomics (9, 10).
During productive infection in vitro, expression of HCMV genes
is conventionally divided into immediate-early, early, and late
phases during a ∼96-h lytic replication cycle. Recently, five
temporal classes of viral protein expression (Tp1 to Tp5) have
been defined by measuring viral protein profiles over the whole
course of infection (11).
Hijacking of the ubiquitin-proteasome system (UPS) to de-
grade host proteins is ubiquitous across many viral families (12).
The proteins degraded by viruses are typically detrimental to
viral replication, and can include antiviral restriction factors or
components of viral sensing pathways, activating immune cell
ligands, and elements of cell death pathways (13, 14). We have
shown previously that >900 host proteins are down-regulated
more than threefold over the course of HCMV infection, with
133 proteins degraded during the early phase, of which 89% are
targeted to the proteasome. These data led directly to the
identification of candidate natural killer (NK) cell ligands and
identified helicase-like transcription factor (HLTF) as an anti-
viral restriction factor (10, 11). However, it is not yet known
which proteins are degraded later during infection, or through-
out a whole infection time course. Furthermore, it is unclear
whether or how HCMV inhibits necroptotic cell death pathways,
which represent a key defense against viral spread within an
infected host (15).
Activation of death receptors such as TRAILR1/2, TNFR1,
and Fas leads to apoptotic cell death via an activating cleavage of
procaspase-8 (16). In the presence of caspase inhibition or lim-
iting levels of ATP, extrinsic apoptosis shifts toward the nec-
roptotic pathway. This is dependent on an interaction between
Receptor Interacting Serine/Threonine Kinases 1 and 3 (RIP1/3)
through their homotypic interaction motif (RHIM) domains
(17). Necroptosis can also be activated by cytoplasmic sensing of
murine cytomegalovirus (MCMV) DNA by Z-DNA-binding
protein 1 (ZBP1), or ligation of Toll-like receptors 3 or 4 (TLR3/4),
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which activate RIP3 through alternative RHIM domain-containing
adaptors (17) (Fig. 1). All three pathways converge with RIP3-
dependent phosphorylation and activation of the pseudokinase
MLKL, which transitions from an inactive monomer to a nec-
roptotic oligomer. The oligomer translocates to and disrupts the
plasma membrane, leading to cell swelling and loss of plasma
membrane integrity, although the exact mechanism of membrane
disruption is unclear (18–20).
Here, a systematic examination of protein degradation at 48 h
of HCMV infection determined that degradation of MLKL was
sustained throughout early and late infection. The data showed
that MLKL was degraded by the minimally passaged Merlin
strain of HCMV, but not by the highly passaged laboratory-
adapted strain AD169. The strain Merlin UL36-encoded viral
inhibitor of caspase-8 activation (vICA/pUL36), which is known
to function as a potent inhibitor of apoptosis, interacted with
MLKL and was necessary and sufficient both to degrade MLKL
and to inhibit TNFα-stimulated necroptosis. Whereas HCMV
strain AD169 sensitized cells to necroptosis, strain Merlin pre-
vented this sensitization. pUL36 is thus a multifunctional cell
death inhibitor capable of inhibiting both apoptotic and necroptotic
pathways.
Results
Host Proteins Targeted for Degradation at 48 h of HCMV Infection.
We applied the proteasomal inhibitor MG132 to build a global
picture of proteins degraded late during HCMV infection.
TERT-immortalized primary human fetal foreskin fibroblasts
(HFFF-TERTs) were infected with HCMV strain Merlin at a
multiplicity of infection (MOI) of 10 for 48 h, with application of
MG132 (or the equivalent amount of dimethyl sulfoxide
(DMSO) as a control) for the final 12 h of infection (Fig. 2A).
MG132 is known to inhibit calpains and lysosomal cathepsins in
addition to the proteasome (10) and was used to generate a
comprehensive list of proteins targeted for degradation by
HCMV rather than to identify proteins specifically degraded by
the proteasome. A total of 8,476 human and 186 viral proteins
were quantified across two biological replicates (Dataset S1,
which includes an interactive “Plotter”). Two ratios and associ-
ated significance values were calculated for each protein: 1)
virus:mock infection and 2) virus + MG132:virus infection
(Fig. 2B). Fifty-two proteins met high-confidence criteria for
degradation, with a fold down-regulation and rescue of >2 and
P < 0.05 for both ratios.
From a comparison with our previous study of HCMV-
induced protein degradation between 2 and 24 h (10), seven
proteins were degraded with high confidence throughout early
and late infection (Fig. 2 C and D). These proteins included
HLTF and Anaphase Promoting Complex subunits 1 and 5
(ANAPC1/5), whose degradation by HCMV has been well
characterized (10, 25). The effector of necroptosis MLKL was
the most significantly down-regulated protein at 48 h of HCMV
infection and was among proteins most significantly rescued by
addition of MG132 (Fig. 2B). In comparison, 37 proteins de-
graded at 48 h did not score highly for degradation at early time
points (10) (Fig. 2 C and E and SI Appendix, Fig. S1A).
Degradation of MLKL Is Mediated by Immediate Early Protein pUL36.
We previously took a systematic approach to identifying the viral
proteins responsible for the degradation of host factors,
employing a panel of recombinant viruses deleted for various
blocks of HCMV genes that are nonessential for replication
in vitro (10). These viruses included strain AD169, a highly
passaged, laboratory-adapted strain that contains a deletion in
the UL/b′ region (encoding 20 canonical genes, UL133-
UL150A), frameshifts in RL5A, RL13, and UL131A, and a
nonsynonymous substitution in UL36 that inactivates the ability
of pUL36 to bind procaspase-8 and inhibit apoptosis (26, 27).
MLKL was down-regulated by strain Merlin viruses but not by
strain AD169, and this was confirmed by immunoblotting
(Fig. 3 A and B). This indicated that one or more differences in
AD169 abrogate virus-mediated MLKL degradation. To identify
viral factors interacting with MLKL, a SILAC immunoprecipi-
tation (IP) was performed in HCMV strain Merlin-infected
HFFF-TERTs stably expressing MLKL tagged with HA at the
C terminus. pUL36 coprecipitated with MLKL, and this was
confirmed by a reciprocal IP (Fig. 3 C and D and Dataset S2).
This interaction was further supported by an immunofluores-
cence study showing cytoplasmic colocalization between MLKL-
HA and pUL36 in stably expressing HFFF-TERTs (SI Appendix,
Fig. S2A). To determine whether pUL36 interacts with inactive,
unphosphorylated MLKL or active, phosphorylated MLKL we
researched the pUL36-V5 SILAC IP data (Fig. 3D) using a vari-
able phosphomodification. All identified MLKL peptides were
unphosphorylated, and encompassed all known sites of activating
phosphomodifications (SI Appendix, Fig. S3). This suggests that
pUL36 interacts with unphosphorylated MLKL but does not ex-
clude an additional interaction with phosphorylated MLKL.
A series of HFFF-TERT cell lines stably expressing strain
Merlin UL36 or each of the individual genes in the UL133-
UL150A region were next screened to determine whether any
other viral protein contributed to MLKL degradation. Expres-
sion of UL36 was sufficient to reduce the level of MLKL by 3.7-
fold (Fig. 3E and SI Appendix, Fig. S2 B–D). MLKL expression
was not modulated more than 2-fold by any other proteins in the
UL/b′ region. Despite substantial variation in the level of ex-
pression of some of the viral proteins, this did not correlate with
relative MLKL abundance (SI Appendix, Fig. S2D). pUL36 could
be detected from 6 hours postinfection (hpi), and was expressed
with Tp2 (temporal protein profile 2) kinetics, matching the ki-
netics of MLKL degradation (11) (Fig. 3F). Finally, infection
with strain AD169 or two independent strain Merlin UL36 de-
letion mutants rescued MLKL, suggesting that pUL36 was nec-
essary as well as sufficient for MLKL degradation (Fig. 3G).
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Fig. 1. The necroptosis pathway and mechanism of action of small molecule
necroptosis inhibitors. Two inhibitors of the necroptotic pathway were uti-
lized in this study: GSK′872, which inhibits RIP3 kinase activity (21, 22), and
necrosulfonamide (NSA), which inhibits downstream effector functions of
MLKL via covalent reaction with human MLKL residue Cys86 (19, 23).
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Fig. 2. Identification of proteins targeted for degradation by HCMV at 48 hpi. (A) Schematic of the experimental method, conducted in biological duplicate.
Cellular lysates from the second 48-h biological replicate were analyzed simultaneously with residual lysates from the 12-h degradation screen in the
Nightingale et al. (10) study, facilitating a direct comparison (SI Appendix, Fig. S1A). Peptides from each sample were labeled with tandem mass tags and
analyzed by MS3 mass spectrometry. (B) Scatterplots of human proteins quantified at 48 hpi in one or both replicates, showing averaged ratios. P values were
estimated using significance B values, then corrected for multiple hypothesis testing (24). K-means clustering suggested there were at least nine different
patterns of protein expression across the samples (Dataset S1C and SI Appendix, Fig. S1B). (C) Overlap between early degradation data from the Nightingale
et al. (10) study (using either stringent or sensitive statistical criteria) and 48 h degradation data presented in this study. (D) Examples of the seven proteins
degraded with high confidence both early and late during infection. MLKL was only quantified in one replicate. Error bars: range. P values were calculated as
described in B. *P < 0.05, **P < 0.001, ***P < 1 × 10−7. Additional proteins were likely to have been degraded both early and late during infection (Dataset S1
and SI Appendix, Fig. S1A), but did not pass the stringent filtering criteria used at one or other of the time points. (E) Examples of the 37 proteins degraded at
48 h that were not confidently degraded at early time points. These comprised: 1) proteins not degraded at early time points (shown in this figure), 2) proteins
that were insufficiently degraded at early time points to pass filtering criteria, and 3) proteins not quantified in the Nightingale et al. (10) study. Additional
examples and the corresponding 12 h data are shown in SI Appendix, Fig. S1A.
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Fig. 3. HCMV strain Merlin pUL36 is necessary and sufficient to degrade MLKL. (A) Relative abundance of MLKL from a proteomic screen of >250 proteins
published in the Nightingale et al. (10) study. HFFF-TERTs were infected with strain Merlin (WT1), WT1 that lacked UL16 and UL18 (WT2), one of six block-
deletion viruses derived from WT1 or WT2, or strain AD169 (MOI = 10, 72 h infection). A z score of >5 was considered significant. (B) Immunoblot confirming
that MLKL is down-regulated by strain Merlin but not by strain AD169 (MOI = 5, 48 h infection, cells lysed in RIPA buffer). MLKL was similarly down-regulated
in cells lysed in 2% SDS (SI Appendix, Fig. S2E). This was consistent with the observed MLKL down-regulation in cells lysed with 6 M guanidine for proteomic
experiments (Fig. 2) and indicated that MLKL was likely degraded as opposed to being translocated to RIPA-insoluble membrane-associated complexes. (C)
SILAC immunoprecipitation of C-terminally HA-tagged MLKL or control in the presence of strain Merlin infection (MOI = 3, 24 h infection in the presence of 10
μMMG132 for the final 12 h). Proteins enriched more than fivefold are shown. P values were estimated using the method of significance A and corrected for
multiple hypothesis testing (24). (D) SILAC immunoprecipitation of C-terminally V5-tagged pUL36 or control in the presence of 10 μMMG132 for 12 h. Proteins
that were enriched more than fivefold are shown, and P values were estimated as described in C. (E) Immunoblot showing that pUL36 is sufficient to down-
regulate MLKL. A series of HFFF-TERT cell lines stably expressing genes in the UL133-150A region were lysed in RIPA buffer and analyzed by immunoblotting.
Confirmation of viral protein expression was achieved by immunoblotting or mass spectrometry (28) (Dataset S3D and SI Appendix, Fig. S2B), except for
pUL136, which was not detected by either method. MLKL was similarly down-regulated by pUL36 in cells lysed in 2% SDS (SI Appendix, Fig. S2F, as shown
during HCMV infection in SI Appendix, Fig. S2E). (F) Temporal profile of strain Merlin pUL36 in whole-cell lysates harvested at different times over the whole
course of infection, from theWeekes et al. (11) study. (G) Immunoblot showing that pUL36 is necessary for down-regulation of MLKL (MOI = 5, 24 h infection).
Cells were infected with WT strain Merlin (Merlin*), a version of Merlin in which intact genes UL128 and RL13 are under tet regulation (Merlin**), two UL36
deletion viruses derived from Merlin**, or strain AD169. ΔUL36ex2 has a deletion in exon 2. (Right) the relative amount of MLKL normalized to GAPDH.
Overall this data suggests that pUL36 is necessary and sufficient to degrade MLKL.
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pUL36 Protects Cells from Necroptosis. Inhibition of caspase-8
during death receptor stimulation shifts extrinsic apoptosis to-
ward the necroptotic pathway (29–31). The HCMV UL36-
encoded viral inhibitor of caspase-8 activation (vICA/pUL36)
inhibits apoptosis by binding the prodomain of caspase-8 and
preventing its proteolytic activation (27). Inhibition of caspase-8
activation by pUL36 would be predicted to promote necroptosis,
but this has not been reported. We therefore sought to deter-
mine whether Merlin pUL36 additionally inhibits necroptosis by
degrading MLKL. In vitro, necroptosis can be stimulated by a
combination of TNFα (T), BV6 (B, an IAP antagonist that
sensitizes cells to TNFα-induced cell death), and the pan-caspase
inhibitor Z-VAD-fmk (Z) (Fig. 4A) (32, 33). Although previous
reports have suggested that HFFFs are not susceptible to nec-
roptosis due to limiting levels of RIP3 (34), both RIP3 and RIP1
were detectable in HFFF-TERTs by proteomics (SI Appendix,
Fig. S4A). Necroptosis was induced by T + B + Z (TBZ) in
HFFF-TERTs as well as in immortalized mouse embryonic fi-
broblasts (MEFs), which are highly susceptible to necroptosis
(35) and were therefore used as a positive control (Fig. 4B). Two
inhibitors were employed to determine whether the stimulated
death pathway was canonical MLKL- and RIP3-dependent
necroptosis (Fig. 1). GSK′872 binds to and inhibits the RIP3
kinase domain (21, 22), whereas necrosulfonamide (NSA) in-
hibits downstream effector functions of MLKL via covalent re-
action with the Cys86 residue of human but not murine MLKL
(19, 23). NSA and GSK′872 inhibited TBZ-induced cytotoxicity
in HFFF-TERTs, indicating that these cells expressed sufficient
RIP3 to induce measurable canonical necroptosis (Fig. 4B).
Omoto et al. (34) previously demonstrated that pUL36 does
not impact the ability of HCMV strain Towne to protect against
necroptosis in fibroblasts stably transduced with RIP3. In con-
trast to this conclusion, we found that strain Merlin pUL36 was
sufficient to inhibit necroptosis (Fig. 4C). The two other HCMV-
encoded inhibitors of apoptosis, pUL37 × 1/vMIA (viral
mitochondria-localized inhibitor of apoptosis) and pUL38 (37,
38), augmented MLKL-dependent necroptosis (as demonstrated
by complete inhibition by NSA). However, cell death was in-
completely inhibited by GSK′872, suggesting that a RIP3-
independent mechanism might be acting in addition (Fig. 4C).
Next, untransduced, control, and UL36-expressing cell lines were
treated with TB or TBZ in parallel to assess the effect of pUL36
on apoptosis and necroptosis, respectively (Fig. 4D). Other in-
hibitors of caspase-8, including MCMV pM36 and the compound
z-VAD-fmk (Z), inhibit death receptor-stimulated apoptosis
while sensitizing cells expressing sufficient levels of RIP3 and
MLKL to necroptosis (29–31). Consistent with these observa-
tions, we detected no change in the overall level of cell death in
untransduced cells when Z was added to TB (Fig. 4 D, Left
leftmost bar and Right leftmost bar). In contrast, pUL36 was able
to inhibit apoptotic cell death stimulated by TB, suggesting that
it was not simply acting as a caspase-8 inhibitor (Fig. 4 D, Left).
Furthermore, in the presence of TBZ apoptosis is potently
inhibited by Z, and pUL36 inhibited necroptotic cell death
(Fig. 4 D, Right). Together these data indicate that pUL36 can
inhibit both apoptosis and necroptosis.
Finally, infection of HFFFs with HCMV strains Merlin and
AD169 for 48 h prior to TBZ stimulation suggested that inhi-
bition of MLKL-dependent necroptosis required functional
pUL36. Preinfection with Merlin had a slight protective effect on
necroptosis, whereas AD169 infection amplified the effect of
TBZ (Fig. 4 E and F). Cell death induced by TBZ after infection
with HCMV also appeared to have a RIP3-independent com-
ponent, as GSK′872 had little inhibitory effect.
Substitution of Merlin pUL36 Cys131 Abrogates Inhibition of
Necroptosis by Abolishing MLKL Binding and Degradation. Strain
Merlin and strain AD169 pUL36 differ by five amino acid
residues (SI Appendix, Fig. S5), including a Merlin Cys131 →
AD169 Arg131 substitution. This single replacement abrogates
inhibition of apoptosis, as pUL36 can no longer bind procaspase-
8 (27). Five Merlin pUL36 mutants corresponding to the five
amino acid substitutions between strain Merlin and strain
AD169 were constructed in order to determine which were im-
portant for degradation of MLKL. Only the C131R substitution
prevented pUL36 from binding and down-regulating MLKL
(Fig. 5 A and B). The same pUL36 mutant was also unable to
protect cells from necroptosis, suggesting that this single residue
plays a key functional role in inhibition of both apoptosis and
necroptosis by pUL36 (Fig. 5C).
Discussion
Herpesviruses persist lifelong in infected individuals by com-
prehensive modulation of adaptive and innate immunity. Mul-
tiple viral proteins are deployed to target host factors for
degradation, many very early during infection (10). The present
study provides a systematic, searchable database that examines
host protein degradation at 48 h of HCMV strain Merlin infec-
tion, ∼50 to 66% of the way through the lytic replication cycle in
HFFFs. In addition to identifying proteins degraded throughout
the HCMV replication cycle, these data may be particularly
useful for identifying which viral protein targets a given host
factor for degradation. We defined previously the kinetics of
expression of the majority of canonical HCMV proteins, which
can now be compared to the kinetics of host protein degradation,
from 6 to 48 h postinfection (10, 11). Other mechanisms of host
protein degradation that are not inhibited by MG132 are also
likely to be subverted by HCMV. However, 87 to 89% of de-
graded proteins were targeted to the proteasome by 24 h
postinfection (10).
The key roles of necroptosis in protecting cell populations
against virus infection are highlighted by the impressive range of
known viral countermeasures. Necroptosis inhibitors are partic-
ularly widespread among herpesviruses, with MCMV and herpes
simplex viruses (HSV) types 1 and 2 encoding conserved RHIM-
domain containing proteins (M45, ICP6, and ICP10, respec-
tively) which compete with host RHIM-domain adaptor proteins
such as RIP1 for binding to RIP3 (39–41). The HCMV M45
ortholog pUL45 does not contain a RHIM domain and does not
inhibit cell death (42). Instead, it had been suggested that
HCMV targets the necroptotic pathway downstream of RHIM
signaling, after RIP3-dependent phosphorylation of MLKL, al-
though the mechanism had not been elucidated (34).
As other viral inhibitors of caspase-8 activation have been
shown to sensitize cells to programmed necrosis (31, 43), it has
been assumed that HCMV pUL36 would have a similar effect,
requiring HCMV to encode a separate mechanism of nec-
roptosis inhibition in order to evade cell death completely.
However, although MCMV M36 can sensitize cells to nec-
roptosis (31), the same phenomenon has not been demonstrated
for HCMV pUL36, which may not be surprising given that both
proteins exhibit only 19% sequence identity (44). The under-
standing of why HCMV pUL36 expression can inhibit death
receptor-stimulated apoptosis instead of stimulating necroptosis
as per the action of other inhibitors of caspase-8 such as z-VAD-
fmk and MCMVM36 (29–31) may have been confounded by the
use of cell lines that are not susceptible to necroptotic cell death
(27). Here, we explain these observations by showing that
HCMV pUL36 mediates the degradation of MLKL and inhibits
necroptosis. In the presence of either UL36 expression or
HCMV Merlin infection, the level of MLKL protein was de-
creased in cells lysed in either 6 M guanidine, RIPA, or 2% SDS,
and subsequently rescued by the addition of MG132. Future
work should confirm that high molarity guanidine and high
percentage SDS do indeed fully solubilize RIPA-insoluble
MLKL complexes that arise in cells undergoing necroptosis.
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Fig. 4. Role of MLKL degradation in HCMV infection. (A) Schematic of the necroptosis assay, which was performed in biological triplicate conducted in
parallel and repeated in two or three completely independent experiments. Cytotoxicity was quantified by measuring lactate dehydrogenase (LDH) release
using the CytoTox 96 non-radioactive cytotoxicity assay (Promega). Cytotoxicity was calculated as a percentage of 100% lysis (from untreated cells lysed with
lysis buffer) after subtraction of background LDH release from live cells. To stimulate apoptosis, cells were treated with TB instead of TBZ. (B) TBZ induces
MLKL- and RIP3-dependent necroptosis, which was inhibitable by GSK′872 in HFFF-TERTs and MEFs. NSA inhibited necroptosis in HFFF-TERTs but not MEFs,
likely because NSA does not inhibit murine forms of MLKL (19). Error bars show SEM. P values were estimated using a two-tailed t test (n = 3). ***P < 0.001,
****P < 0.0001. Data are representative of three independent experiments. To dissect fully the conditions of this assay, stimulation with each of T, B, and Z
alone or in combination was examined in the presence or absence of inhibitors (SI Appendix, Fig. S4 B and C). HFFFs were insensitive to T or Z alone, TZ, or BZ.
Cell death was stimulated by B alone in the absence of death receptor stimulation, an effect that has been observed in other cell types (36) (SI Appendix, Fig.
S4B). The cell death initiated by BV6 was MLKL and RIP3 independent, but also caspase-8-dependent (inhibited by the addition of Z), suggesting that BV6
alone was not responsible for the necroptotic cell death observed in the TBZ condition (SI Appendix, Fig. S4 B and C). Collectively, these results suggest that
only in the presence of TBZ was cell death dependent on MLKL and RIP3. (C) pUL36 is sufficient to inhibit necroptosis in stably transduced HFFF-TERTs treated
with TBZ ± inhibitors. In addition to untransduced cells, two control vectors were employed. “Ctrl” cells were transduced with a vector containing a short,
randomized DNA sequence. pUL24 was included as a control HCMV tegument protein that has a similar size to pUL36 but lacks any known role in cell death.
Error bars: SEM. P values were estimated using a two-tailed t test (n = 3). **P < 0.01, ***P < 0.001, ****P < 0.0001, ns = nonsignificant. Data are repre-
sentative of two independent experiments. (D) pUL36 inhibits both apoptosis and necroptosis. Untransduced, control, or pUL36-expressing HFFF-TERTs were
treated for 18 h with either TB or TBZ to stimulate apoptosis or necroptosis, respectively, in the presence or absence of NSA or GSK′872. Error bars: SEM. P
values were estimated using a two-tailed t test (n = 3). *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. Data are representative of two independent
experiments. (E) Functional pUL36 was required for inhibition of necroptosis, comparing 48 h mock, Merlin, or AD169 infection (MOI = 5) in HFFF-TERTs
subsequently stimulated with TBZ ± inhibitors for 18 h. Baseline cytotoxicity in untreated cells was not subtracted from the other values and is shown as a
separate yellow bar. Error bars: SEM. P values were estimated using a two-tailed t test (n = 3). *P < 0.05, ***P < 0.001, ****P < 0.0001, ns = nonsignificant.
Data are representative of two independent experiments. (F) MLKL-dependent cytotoxicity was calculated from the difference between % cytotoxicity (TBZ
alone) versus (TBZ + NSA), shown by the double-headed arrow in Fig. 4E.
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Previous studies investigating the interaction between HCMV
and necroptosis have employed HFFFs stably transduced with
RIP3 in order to confer susceptibility to necroptosis, which can
otherwise be lost during cell propagation (34). Using these cells,
the authors found that all tested HCMV strains, including
AD169, were able to inhibit TNFα-stimulated necroptosis, al-
though strain Merlin inhibited necroptosis more potently than
AD169, consistent with our results (Fig. 4E). Furthermore,
comparison of a WT strain Towne (encoding pUL36 with a
cysteine at position 131) with a Towne ΔUL36 mutant suggested
that pUL36 was necessary for inhibition of apoptosis but not
necroptosis (34). In addition to mediating cell death, RIP3 has
been implicated in NF-κB and inflammasome activation and can
induce apoptosis when overexpressed (22, 45). It is possible that
overexpression of RIP3 has off-target effects, which may explain
the discrepancy between the previously published work and the
present study; the experimental setting may clearly influence the
outcome observed with pUL36. In addition, while the Omoto
et al. study suggested that HCMV targets necroptosis down-
stream of MLKL phosphorylation, all MLKL peptides in our
pUL36-V5 SILAC IP were unphosphorylated (Fig. 3D and SI
Appendix, Fig. S3), suggesting that pUL36 affects the monomeric
MLKL pool. However, this does not exclude the potential for
additional HCMV-mediated direct or indirect mechanisms of
necroptosis inhibition. Further evidence that results can be de-
pendent on cell type and the presence of RIP3 overexpression
came from use of the Towne ΔUL36 mutant to show that pUL36
can inhibit caspase-independent cell death during late stages of
macrophage differentiation (46). This also suggests that pUL36-
mediated degradation of MLKL may occur in more than one cell
type. The HFFF-TERT cell line used in the present study is
susceptible to RIP3 and MLKL-dependent canonical necroptosis
(Fig. 4B) and may be an invaluable resource for future studies of
viral modulation of cell death.
Necroptotic activation of MLKL can influence many other
cellular processes, including inflammasome activation, endo-
somal trafficking, extracellular vesicle generation, and autophagy
(47–50). It is therefore possible that HCMV-mediated degra-
dation of MLKL may have other consequences for viral patho-
genesis, including effects on virion assembly, trafficking, and
cell-to-cell spread.
Infection of HFFF-TERTs with HCMV prior to TBZ stimu-
lation resulted in induction of a form of cell death that was not
completely inhibited by GSK′872, which is suggestive of an
RIP3-independent but MLKL-dependent mechanism (Fig. 4E).
A similar but less significant effect was observed in cells
expressing the HCMV apoptosis inhibitors pUL37 and pUL38
(Fig. 4C). RIP3-independent necroptosis in fibroblasts has been
reported previously by others (35) but remains poorly charac-
terized. Infection with HCMV strain AD169, which lacks a
functional pUL36 protein, sensitized cells to necroptosis
(Fig. 4E), in accord with the observed increase in MLKL protein
upon infection with viruses deficient in functional pUL36
(Fig. 3G). This is likely to be due to IFN-mediated up-regulation
of MLKL (51). Strain Merlin protein pUL36 was able to coun-
teract the effect of necroptosis sensitization, rather than abro-
gating necroptosis entirely (Fig. 4E).
pUL36 can bind both procaspase-8 (27) and MLKL, facili-
tating potent inhibition of both apoptosis and necroptosis. In-
deed, these two functions can be inhibited by the same single
amino acid substitution gained during passage of HCMV in cell
culture (26, 27). This suggests that a larger cell death complex
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may form from the caspase-8:FADD:RIP1 FADDosome/
Ripoptosome (52–54) and the RIP1:RIP3 necrosome (17), en-
abling an interaction between pUL36, caspase-8, and MLKL.
Examination of this hypothesis, including an investigation of
whether binding of pUL36 to caspase-8 is a necessary interme-
diary for binding to MLKL, would be of significant interest to
the field.
HCMV pUL36 and its orthologs belong to the US22 family of
herpesvirus proteins, which characteristically feature a set of
motifs I to IV (44). Cys131, which is found within motif III, is
conserved within the primate cytomegaloviruses but is replaced
by conservative substitutions in rodent cytomegalovirus orthologs
that do not abrogate apoptosis inhibition. In addition, the
MCMV ortholog pM36, which displays only 19% sequence
similarity to HCMV pUL36 and lacks the region that includes
Cys131, is still an efficient suppressor of apoptosis (44). This
suggests that the Arg131 residue of strain AD169 pUL36 may
restrict cell death inhibition, as opposed to Cys131 being required
for this function.
Only four drugs are currently available for treating HCMV, all
exhibiting significant adverse effects and the potential of drug
resistance. The identification of a potentially inhibitable inter-
action between a single residue of a viral antagonist and key
mediators of both necroptosis and apoptosis may therefore be of
substantial therapeutic significance. In addition to pUL36-
MLKL, other interactions involving distinct antiviral pathways
could be targeted simultaneously to potently inhibit viral repli-
cation, for example between HCMV pUL145 and the recently
identified restriction factor HLTF (10). Moreover, our data are
likely to identify further proteins that have roles in restricting
infection by HCMV or other viruses.
Materials and Methods
Extended materials and methods can be found in SI Appendix.
Viral Infections. The required volume of viral stock to achieve the MOI de-
scribed in the results section was diluted in serum-free Dulbecco’s Modified
Eagle Medium (DMEM), mixed gently and applied to HFFF-TERTs. Mock in-
fections were performed identically but with DMEM instead of viral stock.
Time 0 was considered the time at which cells first came into contact with
virus. Cells were incubated with virus for 2 h at 37 °C on a rocking platform,
and then the medium was replaced with DMEM + 10% fetal bovine
serum (FBS).
Proteomic Screen. HFFFs-TERTs were infected as described above in biological
duplicate at an MOI of 10. At 36 hpi, 10 μMMG132 or the equivalent volume
of DMSO was added to the cells for the last 12 h of infection. Samples from
the second replicate were digested and analyzed with residual samples from
the 12-h degradation screen from the Nightingale et al. (10) study. Methods
for whole cell lysate protein preparation and digestion, peptide labeling
with tandem mass tags, HpRP fractionation, liquid chromatography-mass
spectrometry, and data analysis are discussed in detail in the Nightingale
et al. (10) study and recapitulated in SI Appendix.
Immunoblotting. Cells were lysed, sonicated, and clarified by centrifugation,
and protein concentration was measured using a bicinchoninic acid (BCA)
assay. Samples were denatured and reduced, and then the proteins were
separated by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis
(PAGE), transferred to a polyvinylidene difluoride (PVDF) membrane (0.45 μm
pore), and probed using the primary and secondary antibodies detailed in SI
Appendix. Fluorescent signals were detected using the Odyssey CLx Imaging
System (LI-COR), and images were processed and quantified using Image
Studio Lite V5.2 (LI-COR).
Plasmid Construction and Transduction. Lentiviral expression vectors encoding
MLKL-HA, the V5-tagged viral proteins pUL36 and pUL133-pUL150A and
controls, were synthesized by PCR amplification of the genes and cloning
them into Gateway vectors (55). V5-tagged UL36 point mutants were gen-
erated by PCR site-directed mutagenesis. The primers and templates used
are described in SI Appendix. Stable cell lines were generated by transduc-
tion with lentiviruses produced via the transfection of HEK293T cells with
lentiviral expression vectors and helper plasmids.
Immunoprecipitation. Cells were harvested in lysis buffer, tumbled on a ro-
tator and then clarified by centrifugation and filtration. After incubation
with immobilized mouse monoclonal anti-V5 or anti-HA agarose resin,
samples were washed and then subjected either to immunoblotting or mass
spectrometry (SI Appendix).
Cell Death Assays. For assays in the absence of infection, 96-well plates were
seeded with HFFF-TERTs or immortalized MEFs and incubated for 24 h. Cells
were incubated for 18 h with 30 ng/mL TNFα, 5 μM BV-6, and/or 25 μM
z-VAD-fmk in the presence or absence of 0.5 μM necrosulfonamide (NSA) or
1.5 μM GSK′872, or DMSO alone (control). Half of the control cells were lysed
to measure lactate dehydrogenase (LDH) release from maximally lysed cells.
The other half were used to measure background LDH release from live,
untreated cells. LDH release was measured using the CytoTox 96 Non-
Radioactive Cytotoxicity Assay. Average absorbance values derived from
culture medium alone were subtracted from each absorbance value from
experimental wells. For assays in the presence of infection, HFFF-TERTs were
seeded into 96-well plates, incubated for 24 h, and infected with HCMV
(MOI = 5). The medium was changed 48 h after infection to stimulate
necroptosis as described above.
Data and Materials Availability Statement. The mass spectrometry proteomics
data have been deposited to the ProteomeXchange Consortium (www.
proteomexchange.org/) via the PRIDE partner repository (56) with the
dataset identifier PXD017279 (57). All materials described in this manuscript,
and any further details of protocols employed, can be obtained on request
from the corresponding author by email to mpw1001@cam.ac.uk.
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